BioLamina AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioLamina AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11241
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioLamina AB (BioLamina) is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xeno-free laminin proteins. Its product portfolio includes Laminin-521, a recombinant human protein, which is the natural laminin for pluripotent stem cells; Laminin-111, for early epithelial development and differentiation of the epiblast; and LAMscreen. BioLamina’s products find application in maintaining skeletal muscle cells; kidney, intestinal and endothelial cells; cancer cells, animal stem cells and other neural cells. The company offers its products through a network of distributors in Asia, Europe and the Americas, among others. BioLamina is headquartered in Stockholm, Sweden.

BioLamina AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioLamina AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BioLamina AB, Medical Devices Deals, 2012 to YTD 2018 9
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BioLamina AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
BioLamina and Novo Nordisk Enter into Partnership 11
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 12
Licensing Agreements 13
BioLamina Enters into Licensing Agreement with Cevec Pharma 13
BioLamina Enters Into Licensing Agreement With Vitrolife For Cryopreservation Medium 14
Acquisition 15
Vitrolife Acquires 4.6% Stake In Biolamina For US$0.6 Million 15
BioLamina AB – Key Competitors 16
BioLamina AB – Key Employees 17
BioLamina AB – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Product News 19
May 02, 2018: BioLamina Launches a Cell Therapy Grade Stem Cell Culture Matrix, Biolaminin 521 CTG, Bridging Discovery and Clinical Cell Therapy 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
BioLamina AB, Pharmaceuticals & Healthcare, Key Facts 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioLamina AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioLamina AB, Deals By Therapy Area, 2012 to YTD 2018 8
BioLamina AB, Medical Devices Deals, 2012 to YTD 2018 9
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BioLamina and Novo Nordisk Enter into Partnership 11
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 12
BioLamina Enters into Licensing Agreement with Cevec Pharma 13
BioLamina Enters Into Licensing Agreement With Vitrolife For Cryopreservation Medium 14
Vitrolife Acquires 4.6% Stake In Biolamina For US$0.6 Million 15
BioLamina AB, Key Competitors 16
BioLamina AB, Key Employees 17
BioLamina AB, Subsidiaries 18

List of Figures
BioLamina AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioLamina AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BioLamina AB, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[BioLamina AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Solaria Energia y Medio Ambiente S.A. (SLR)-エネルギー分野:企業M&A・提携分析
    Summary Solaria Energia y Medio Ambiente, S.A. (Solaria) is a manufacturer and supplier of photovoltaic (PV) modules and cells, and provider of turnkey projects. It designs, manufactures, supplies, and installs PV and thermal solutions for power generation. Its product portfolio includes PV modules …
  • Pluristem Therapeutics Inc (PSTI):企業の財務・戦略的SWOT分析
    Summary Pluristem Therapeutics Inc (Pluristem) operates as a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. Its PLacental eXpanded (PLX) cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. T …
  • St. Joseph Health:企業の戦略的SWOT分析
    St. Joseph Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Hanmi Pharmaceuticals Co Ltd (128940):企業の財務・戦略的SWOT分析
    Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Guangzhou Boji Medical & Biotechnological Co Ltd (300404):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Boji Medical & Biotechnological Co Ltd (BOJI) is a contract research organization. The organization provides services including regulatory affairs, preclinical research, clinical trials I-IV, PMS, clinical trial for medical devices, post marketing studies (PMS), data management and …
  • Marshall of Cambridge (Holdings) Ltd:企業の戦略的SWOT分析
    Marshall of Cambridge (Holdings) Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Macquarie Infrastructure Corporation:企業のM&A・事業提携・投資動向
    Macquarie Infrastructure Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Macquarie Infrastructure Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Bm-Bank Public Joint Stock Company:企業の戦略・SWOT・財務分析
    Bm-Bank Public Joint Stock Company - Strategy, SWOT and Corporate Finance Report Summary Bm-Bank Public Joint Stock Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Liberty Star Uranium & Metals Corp (LBSR):企業の財務・戦略的SWOT分析
    Summary Liberty Star Uranium & Metals Corp (Liberty Star), formerly Liberty Star Gold Corp is a mining and mineral exploration and development company that offers mineral resources. The company offers acquisition, exploration, operations, management, mining, production, and development of gold, copp …
  • Key Petroleum Ltd (KEY):企業の財務・戦略的SWOT分析
    Summary Key Petroleum Ltd (Key Petroleum) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company carries out projects such as Canning Basin and Perth Basin. It holds interest in exploration permits such as EP 438, EP 448, EP 104/ …
  • EyeGate Pharmaceuticals Inc (EYEG):企業の財務・戦略的SWOT分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • SHL TeleMedicine Ltd (SHLTN):医療機器:M&Aディール及び事業提携情報
    Summary SHL TeleMedicine Ltd (SHL) is a provider of advanced personal telemedicine systems and solutions. The company's staff monitors the health of patients to minimize the need for emergency intervention and hospitalization. Its product portfolio includes ECG transmitters, oximeter, and hand held …
  • Allenex AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Allenex AB (Allenex), formerly LinkMed AB, a subsidiary of CareDx Inc, is a blood stemcells and organs transplantation service provider. The company offers olerup SSP and absorber. Its oleruu is used before the transplantation. Allenex offers pre transplantation, transplantation and post tra …
  • AGF Management Ltd:企業の戦略・SWOT・財務分析
    AGF Management Ltd - Strategy, SWOT and Corporate Finance Report Summary AGF Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MAN Energy Solutions SE:企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Petrosibir AB (SHEL B):企業の財務・戦略的SWOT分析
    Summary Petrosibir AB (Petrosibir) formerly Shelton Petroleum AB, is an oil and gas company. The company offers exploration and development of oil and gas assets and the resource-rich basins in Russia and Ukraine. It holds Ayazovskoye production license and Rustamovskoye exploration license that cov …
  • PetroEnergy Resources Corp (PERC):企業の財務・戦略的SWOT分析
    Summary PetroEnergy Resources Corp (PERC) is a diversified company that offers oilfield and energy services. The company’s services include upstream oil and gas exploration and development, power generation, and renewable energy development services, among others. It undertakes renewable energy proj …
  • Deutsche Telekom AG:戦略・SWOT・企業財務分析
    Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Diana S.A.S.:戦略・SWOT・企業財務分析
    Diana S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Diana S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Pharco Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharco Pharmaceuticals Inc (Pharco Pharmaceuticals), a subsidiary of Pharco Corp, is a manufacturer of branded and generic pharmaceutical products. The company offers products such as alambupine, alfatral, amlodipine, amrase, amrizole, bisadyl, bromhexine, carbolase, ciprofloxacin, dexametha …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆